Entity usage

This page lists pages that use the given entity (e.g. Q42). The list is sorted by descending page ID, so that newer pages are listed first.

Showing below up to 17 results in range #1 to #17.

Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis: Label: en
A General Framework for Treatment Effect Estimators Considering Patient Adherence: Label: en
Analysis of Clinical Dose–Response in Small-Molecule Drug Development: 2009–2014: Label: en
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints: Label: en
Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test: Label: en
A Multivariate Williams-Type Trend Procedure: Label: en
An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials: Label: en
Quantifying Replicability and Consistency in Systematic Reviews: Label: en
Bayesian Inference on Risk Differences: An Application to Multivariate Meta-Analysis of Adverse Events in Clinical Trials: Label: en
On the Use of Co-Data in Clinical Trials: Label: en
Multiple Testing in Group Sequential Trials Using Graphical Approaches: Label: en
Optimal Designs for Multi-Arm Phase II/III Drug Development Programs: Label: en
Evaluating Misclassification Effects on Single Sequential Treatment in Sequential Multiple Assignment Randomized Trial (SMART) Designs: Label: en
Hierarchical Bayesian Benefit–Risk Modeling and Assessment Using Choice Based Conjoint: Label: en
Borrowing From Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines: Label: en
Meta-Analysis of Clinical Dose–Response in a Large Drug Development Portfolio: Label: en
Statistical Inference on the Estimators of the Adherer Average Causal Effect: Label: en